Semaxanib is a quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Semoxind, Romiplate, Z-Semaxanib and SU 5416. Its PubChem CID is 5329098.
Semaxanib
| CAS No | 194413-58-6 |
|---|---|
| Molecular Formula | C15H14N2O |
| Molecular Weight | 238.28 g/mol |
| Synonyms | (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Semaxanib is a quinolone derivative with potential antineoplastic activity.
The listed CAS number is 194413-58-6.
The listed molecular formula is C15H14N2O.
The listed molecular weight is 238.28 g/mol.
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one.
The source lists Semoxind, Romiplate, Z-Semaxanib and SU 5416.